NCT02303171

Use of Warfarin After the First Trimester in Pregnant Women With APS

Use of Warfarin After the First Trimester in Pregnant Women With Antiphospholipid Syndrome

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Mohamed Sayed Abdelhafez · Academic / Other
• Sex: Female
• Age: 20 Years – 38 Years
• Healthy volunteers: Not accepted

Summary

Evaluation of shifting to oral vitamin K antagonist after the first trimester instead of using low molecular weight heparin (LMWH) throughout pregnancy in pregnant women with antiphospholipid syndrome (APS)

Detailed description

Women will be randomly divided into two groups; one will be subjected to anticoagulant therapy by Enoxaparin throughout pregnancy and the other will be subjected to anticoagulant therapy by Enoxaparin in the first trimester then Warfarin after the first trimester until termination of pregnancy.

Conditions

• Recurrent Miscarriage
• Antiphospholipid Syndrome

Interventions

Type	Name	Description
DRUG	Enoxaparin	Women will be given Enoxaparin throughout pregnancy in a dose of 40 mg/day subcutaneously (SC)
DRUG	Warfarin	Women will be given Enoxaparin (40 mg/day SC) in the first trimester then Warfarin (3-5 mg/day) after the first trimester until termination of pregnancy

Timeline

• Start date: 2014-11-01
• Primary completion: 2024-12-01
• Completion: 2025-06-01
• First posted: 2014-11-27
• Last updated: 2023-10-31

Locations

2 sites across 1 country: Egypt